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74Type VI Collagen Regulates Dermal Matrix
Assembly and Fibroblast Motility
Georgios Theocharidis1, Zoe Drymoussi1, Alexander P. Kao2, Asa H. Barber2,3, David A. Lee2,
Kristin M. Braun1 and John T. Connelly1Type VI collagen is a nonfibrillar collagen expressed in many connective tissues and implicated in extracellular
matrix (ECM) organization. We hypothesized that type VI collagen regulates matrix assembly and cell function
within the dermis of the skin. In the present study we examined the expression pattern of type VI collagen in
normal and wounded skin and investigated its specific function in new matrix deposition by human dermal
fibroblasts. Type VI collagen was expressed throughout the dermis of intact human skin, at the expanding
margins of human keloid samples, and in the granulation tissue of newly deposited ECM in a mouse model of
wound healing. Generation of cell-derived matrices (CDMs) by human dermal fibroblasts with stable knock-
down of COL6A1 revealed that type VI collagen-deficient matrices were significantly thinner and contained
more aligned, thicker, and widely spaced fibers than CDMs produced by normal fibroblasts. In addition, there
was significantly less total collagen and sulfated proteoglycans present in the type VI collagen-depleted
matrices. Normal fibroblasts cultured on de-cellularized CDMs lacking type VI collagen displayed increased
cell spreading, migration speed, and persistence. Taken together, these findings indicate that type VI collagen is
a key regulator of dermal matrix assembly, composition, and fibroblast behavior and may play an important role
in wound healing and tissue regeneration.
Journal of Investigative Dermatology (2016) 136, 74-83; doi:10.1038/JID.2015.352INTRODUCTION
Cutaneous wound healing is a complex and dynamic set of
processes that begins after injury and is required to re-
establish skin integrity and function. Three overlapping pha-
ses of wound healing have been described: inflammation,
tissue formation, and tissue remodeling. Extracellular matrix
(ECM) synthesis, assembly, and organization occur during the
latter two phases and are essential for restoring tissue strength
and structure (Singer and Clark, 1999). Dermal fibroblasts are
the main cell type responsible for ECM synthesis, and
dysfunctional matrix deposition has been implicated in both
chronic, nonhealing wounds and scar formation (Caskey
et al., 2014; Herrick et al., 1992; Xue and Jackson, 2013).
Deciphering the function of specific regulatory molecules
involved in these processes could offer new insights into
impaired wound healing and identify therapeutic targets for
wound repair and tissue regeneration.1Centre for Cell Biology and Cutaneous Research, Barts and the London
School of Medicine and Dentistry, Queen Mary, University of London,
London, United Kingdom; 2Institute of Bioengineering, School of
Engineering and Materials Science, Queen Mary, University of London,
London, United Kingdom; and 3School of Engineering, University of
Portsmouth, Portsmouth, United Kingdom
Correspondence: John T. Connelly, Centre for Cell Biology and Cutaneous
Research, Barts and the London School of Medicine and Dentistry, Queen
Mary, University of London, 4 Newark Street, London E1 2AT, UK. E-mail:
j.connelly@qmul.ac.uk
Abbreviations: CDM, cell-derived matrix; ECM, extracellular matrix; NTC,
nontargeting control; PBS, phosphate-buffered saline; sh1, shRNA1; sh2,
shRNA2; shRNA, short hairpin RNA; UCMD, Ullrich congenital muscular
dystrophy
Received 31 March 2015; revised 16 July 2015; accepted 17 August 2015;
accepted manuscript published online 9 September 2015
Journal of Investigative Dermatology (2016), Volume 136 ª 2015 The AType VI collagen is a nonfibrillar collagen that is expressed
in many connective tissues and implicated in matrix organi-
zation. The monomeric unit of type VI collagen is a hetero-
trimer composed of three a chains: a1(VI), a2(VI), and a3(VI).
The biosynthesis of type VI collagen entails intracellular
assembly of the three chains into monomers, dimers, and
tetramers, followed by secretion and extracellular formation
of beaded microfilaments, which are next deposited in the
ECM (Chu et al., 1988; von der Mark et al., 1984). Three new
chains that closely resemble a3(VI) were identified: a4(VI),
a5(VI), and a6(VI) (Fitzgerald et al., 2008; Gara et al., 2008).
Unlike a3(VI), however, their distribution is limited to spe-
cific tissues such as skeletal muscle, myocardium, and
reproductive organs (Fitzgerald et al., 2013; Gara et al.,
2011; Sabatelli et al., 2011).
Type VI collagen interacts with a multitude of key ECM
components, including fibrillar collagens type I (Bonaldo et al.,
1990) and II (Bidanset et al., 1992), basement membrane type
IV collagen (Kuo et al., 1997), fibronectin (Fitch et al., 1991),
glycosaminoglycans hyaluronan and heparin (Specks et al.,
1992), and proteoglycans perlecan (Tillet et al., 1994), bigly-
can, anddecorin (Wiberg et al., 2001).Within connective tissue
ECM, type VI collagen forms a highly branched filamentous
meshwork that encircles thefibers of principal fibrillar collagens
type I, II, and III. In addition, in part via interactionswith type IV
collagen in basement membranes, it anchors blood vessels,
nerves, and mesenchymal cells (Keene et al., 1988; Kuo et al.,
1997). It also serves as a repository for platelet-derived growth
factor (Somasundaram and Schuppan, 1996); keratinocyte
growth factor (Ruehl et al., 2002); matrix metalloproteinases-1,
-2, -3, -8, and -9 (Freise et al., 2009); IL-2 (Somasundaramet al.,
2000); and cytokine oncostatinM (Somasundaramet al., 2002),
thus mediating their activity and availability.uthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
G Theocharidis et al.
Type VI Collagen in Dermal Matrix AssemblyMutations in any of the three genes that encode the type VI
collagen chains (COL6A1, COL6A2, and COL6A3) cause
disorders that affect muscle and connective tissue, with
clinical features that include muscular weakness and joint
contractures and laxity. The two most significant diseases
associated with type VI collagen are Ullrich congenital
muscular dystrophy (UCMD) and Bethlem myopathy (Bushby
et al., 2014). Notably, abnormal skin findings have been re-
ported in many Bethlem myopathy and UCMD patients, such
as follicular hyperkeratosis, hypertrophic and keloid scarring,
dry skin, and striae rubra (Brin˜as et al., 2010; Collins et al.,
2012; Jimenez-Mallebrera et al., 2006; Saroja et al., 2013).
Type VI collagen is expressed throughout the dermis of the
skin and regulates hair follicle cycling (Chen et al., 2015), but
its complete function within the tissue has yet to be
determined.
Based on the interactions with other ECM molecules, we
hypothesized that type VI collagen directs matrix assembly
and influences dermal cell behavior. This study therefore
aimed to determine the function of type VI collagen within
the dermis by analyzing cell-derived matrices (CDMs)
generated by normal and COL6A1-deficient human dermal
fibroblasts. Our results indicate that type VI collagen regu-
lates both the organization and composition of de novo ECM.
Importantly, these changes in the ECM have a significant
impact on fibroblast morphology and migration. Together,
our findings provide insight into the biological function of
type VI collagen within the skin and suggest a key role in
wound healing and tissue repair.
RESULTS
Type VI Collagen Expression in Normal, Keloid Scars
and Acute Wound Healing
Immunofluorescence detection of type VI collagen in frozen
sections of human neonatal foreskin samples revealed that
type VI collagen was widely distributed throughout the
papillary dermis, reticular dermis, and hypodermis with a
higher expression in the papillary dermis (Figure 1a). A similar
expression pattern was observed in adult skin samples with
type VI collagen present throughout the dermis, most promi-
nently in the papillary dermis and around the vasculature
(Figure 1b). Keloid scarring is a pathological wound healing
condition characterized by excessive matrix deposition and is
thought to advance via a tongue-like expanding edge under-
neath the healthy epidermis and papillary dermis (Bran et al.,
2009). Consistent with a role in ECM assembly, type VI
collagen was highly expressed at the edges of keloid scars
(Figure 1c). This pattern was observed for all six patient sam-
ples examined, which included different ethnicities and scar
locations (see Supplementary Figure S1 and Table S1 online),
and was distinct from the pattern of type I collagen and
fibronectin, which were observed more uniformly throughout
the papillary and reticular dermis (Figure 1d and e). Type III
collagen, which also has a role in matrix assembly (Brisson
et al., 2015), localized to the papillary dermis and the lead-
ing edge of keloids, similar to type VI collagen (Figure 1f).
To determine the spatial and temporal expression pattern of
type VI collagen during normal wound healing, full-thickness
5-mm biopsy wounds were made on the back skin of C57BL/
6 mice. Immunofluorescence staining revealed that type VIcollagen was most prominently expressed around the wound
edges (white arrows) on days 1 and 3 but not within the
wound (Figure 1g and h). On day 7, however, type VI
collagen notably increased throughout the granulation tissue
within the re-epithelialized wound (Figure 1i). These results
are consistent with previous findings (Chen et al., 2015) and
suggest an involvement of type VI collagen in cutaneous
wound repair, as it is deposited in the early stages of new
tissue formation within the dermis.
Generation of COL6A1 Knockdown Dermal Fibroblast
Cell Lines and CDMs
To investigate how type VI collagen regulates matrix assem-
bly by human dermal fibroblasts, we developed an in vitro
model of de novo matrix synthesis using the neonatal foreskin
fibroblast cell line HCA2, immortalized with human telo-
merase reverse transcriptase (Stephens et al., 2004). Quanti-
tative reverse transcriptase PCR analysis confirmed that these
cells retain 40% COL6A1 expression compared with primary
fibroblasts, whereas primary keratinocytes express negligible
levels (Figure 2a). Lentiviral transduction of three different
short hairpin RNA (shRNA) constructs and a nontargeting
control (NTC) was used to develop fibroblast lines with stable
knockdown of COL6A1. Western blot analysis demonstrated
nearly complete knockdown of type VI collagen for shRNA1
treatment, partial knockdown for shRNA2, and no knock-
down for shRNA3 (Figure 2b, bottom). This result was
corroborated at the messenger RNA level with quantitative
reverse transcriptase PCR analysis, which showed 95%
knockdown for shRNA1 and 60% knockdown for shRNA2
(Figure 2b, top). Only shRNA3 adversely affected metabolic
activity (see Supplementary Figure S2 online). Based on these
findings, shRNA1 (sh1) and shRNA2 (sh2) were selected for
further experiments.
These cell lines were subsequently used to produce CDMs,
as outlined in Figure 2c. Allowing cells in long-term culture to
create their own ECM yields a naturally synthesized three-
dimensional and organized ECM structure that can function
as a tissue engineering scaffold with in vivo-like features
(Cukierman et al., 2001; Ishikawa et al., 1997). Immunofluo-
rescence staining of the decellularizedmatrices confirmed the
low quantity of type VI collagen in the sh1 CDM (Figure 2d,
bottom) as opposed to a type VI collagen richmatrix generated
from NTC cells (Figure 2d, top). No compensatory effects of
COL6A1 knockdown on gene expression of other type VI
collagen chains (COL6A2, COL6A3, COL6A5, and COL6A6),
other collagen types, or fibronectin were detected (see
Supplementary Figure S3). At the protein level, depletion of the
a1(VI) chain prevented release of a2(VI) into the media, and
both the a2(VI) and a3(VI) chains were retained intracellularly
(see Supplementary Figure S4a online). We confirmed that this
intracellular retention did not activate an unfolded protein
response, because there were no significant changes in
messenger RNA levels of unfolded protein response genes after
COL6A1 knockdown (Supplementary Figure S4b) (Hicks et al.,
2014; Pan et al., 2013).
Type VI Collagen Regulation of ECM Structure
and Composition
To determine the role of type VI collagen in de novo ECM as-
sembly, CDMs were produced from sh1, sh2, and NTC HCA2www.jidonline.org 75
Figure 1. Type VI collagen expression in normal and wounded skin. (a) Representative image of type VI collagen localization (red) in frozen sections of
neonatal foreskin. (b and c) Representative images of type VI collagen localization (red) in paraffin-embedded sections of (b) adult abdominal skin or (c)
abdominal keloid scars. Samples were co-stained for keratin 14 or CD31 (green) to demarcate the epidermis or blood vessels, respectively. Keloid sections were
also stained for type I collagen (d), type III collagen (e), and fibronectin (f). Arrows indicate the scar edge. (gei) Immunofluorescence images of type VI collagen
(red) and keratin 14 (green) in frozen sections of wounded mouse skin at days (g) 1, (h) 3, and (i) 7 after wounding. Excisional wounds were made on the back
skin of 6e8-week-old male C57Bl/6 mice using a 5-mm biopsy punch. Arrows denote wound margins. F, fibrin clot; GT, granulation tissue; NE, neoepidermis.
Scale bars: 100 mm. Insets are 2 zoom.
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Figure 2. shRNA-mediated
knockdown of COL6A1 in dermal
fibroblasts. (a) Quantification of
COL6A1 expression in cultured
primary human dermal fibroblasts
(primary FBs), HCA2 fibroblasts, and
primary human keratinocytes by
quantitative reverse transcriptase
PCR. Expression was normalized to
GAPDH and expressed relative to
primary fibroblasts. (b) Quantitative
reverse transcriptase PCR analysis of
COL6A1 expression in HCA2 cells
transduced with COL6A1 shRNA
constructs (sh1 and sh2) or
nontargeting control (NTC) constructs,
normalized to GAPDH and expressed
relative to NTC. Western blot analysis
of type VI collagen expression in cells
transduced with COL6A1 shRNA
constructs (sh1, sh2, and sh3),
transduced with NTC constructs,
or untreated (UT). (c) Schematic
of procedure for generation of
cell-derived matrices (CDMs). (d)
Representative immunofluorescence
images of type VI collagen deposition
in CDMs generated by NTC and sh1
expressing cells after 10 days in
culture. Data represent mean  s.e.m.
(n ¼ 6). Scale bars: 25 mm.
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Type VI Collagen in Dermal Matrix Assemblycell lines. The COL6A1 knockdown cells (sh1 and sh2)
generated matrices with more aligned fibronectin fibers, as
evidenced by both the representative immunofluorescence
images (Figure 3a) and the corresponding directionality anal-
ysis (Figure 3b), which indicates the frequency of alignment
angles for the fibers. The level of alignment was quantified by
calculating the standard deviation of the Gaussian distribu-
tions of all the directionality histograms, and the fibronectin
fibers of sh1- and sh2-derived matrices had significantly nar-
rower distributions of fiber orientations than the control
matrices (Figure 3c, second graph). The thickness of the entire
matrix was also found to be significantly greater for the control
comparedwith the sh1 and sh2matrices (Figure3c, first graph).
Finally, sh1 cells generated thicker fibers and had greater
interfibrillar spacing compared with control and sh2
(Figure 3c, third and fourth graphs). The intermediate changes
in total matrix thickness and fiber alignment with the partial
knockdown (sh2) indicate a dose-dependent and specific ef-
fect of COL6A1 knockdown on ECM organization. Sh1 and
NTC cell lines were used in all further experiments.To specify when the effects of type VI collagen depletion
arise, fibronectin organization was examined over a 10-day
time course. On day 3 the matrices appeared to be similar,
but by day 5 the differences in alignment were noticeable
and intensified for subsequent time points (Figure 3d). The
above findings were validated with scanning electron
microscopy images of the CDMs on days 5 and 10. The
control matrices were composed of a dense network of
intertwined, mostly randomly oriented fibers, whereas sh1
matrices were sparser, with thicker, highly aligned fibers
(Figure 3e). This distinctive alignment of fibronectin fibers
was also exhibited by matrices obtained by primary fibro-
blasts with COL6A1 knockdown, confirming that the HCA2
model accurately reflects the behavior of primary fibroblasts
(see Supplementary Figure S5 online). We therefore conclude
that type VI collagen is required for fibroblasts to assemble a
dense ECM with small randomly aligned fibers.
To gain further understanding of how type VI collagen
affects matrix composition, the CDMs were stained with
antibodies against a panel of ECM proteins (Figure 4a). Type Iwww.jidonline.org 77
Figure 3. Type VI collagen mediates ECM assembly. (a) Representative immunofluorescence images of fibronectin (Fn) fibers of cell-derived matrices (CDMs)
generated by HCA2 cells expressing nontargeting control (NTC), sh1, or sh2 shRNA after 10 days in culture. (b) Corresponding histograms of fiber orientation
distribution for representative images in a. (c) Quantification of total CDM thickness, Gaussian standard deviation of fiber orientation, interfibrillar space, and
fiber diameter for CDMs produced by NTC, sh1, or sh2 expressing cells. Data represent mean  s.e.m. (3 experiments, 15 images per experiment). *P < 0.05,
***P < 0.001 versus NTC, , ## P < versus sh2, and ###P < 0.001 versus sh2. (d) Representative images of Fn fibers produced by NTC or sh1 expressing cells at
days 3, 5, 7, and 10. (e) Scanning electron microscopy images of CDMs at days 5 and 10. Scale bars: 25 mm for a and d and 10 mm for e.
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Figure 4. Type VI collagen affects extracellular matrix composition. (a) Representative immunofluorescence images of type I collagen, vitronectin, tenascin
C, versican, and decorin in cell-derived matrices (CDMs) generated by nontargeting control (NTC) and sh1 expressing cells. (bee) Quantification of biochemical
composition of CDMs, including (b) soluble collagen using the Sircol assay, (c) total collagen using the hydroxyproline assay, (d) DNA content using the Hoechst dye
assay, and (e) sulfatedglycosaminoglycancontent using theDimethylmethyleneBlueassay.Data representmean s.e.m. (3 experiments). *P< 0.05. Scale bars: 25mm.
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Type VI Collagen in Dermal Matrix Assemblycollagen was more abundant in the control matrices, which
also retained their random alignment and thinner fiber
network. Tenascin C and vitronectin were present at similar
levels in both CDMs and appeared throughout the fibrillar
network. Versican appeared in “pockets” within the CDM
with a higher level in the NTC matrices. Finally, similar levels
of decorin were observed on both CDMs. Biochemical assaysquantitatively confirmed the immunofluorescence findings.
Both pepsin acid-soluble, undenatured collagen measured
with the Sircol (Biocolor, Carrickfergus, UK) assay and total
collagen content measured with the hydroxyproline assay
were significantly higher for control CDMs compared with
sh1matrices (Figure 4b andc). ControlCDMscontainedhigher
sulfated glycosaminoglycan content than sh1, as quantifiedwww.jidonline.org 79
G Theocharidis et al.
Type VI Collagen in Dermal Matrix Assembly
80with the Dimethylmethylene Blue assay (Figure 4d). The
different matrices contained the same number of cells:
approximately 180,000 cells (Figure 4e). Collectively, these
findings demonstrate that type VI collagen regulates the
composition of ECM deposited by dermal fibroblasts.
Effect of Type VI Collagen on Human Dermal Fibroblast
Spreading and Motility
We next interrogated how loss of type VI collagen in the ECM
influenced cell behavior. Primary foreskin dermal fibroblasts
at passage five were seeded onto de-cellularized control and
knockdown CDMs, and cell spreading, morphology, prolif-
eration, differentiation, alignment, and migration were
assessed. Two-dimensional fibronectin-coated glass cover-
slips were used as an additional comparison. After 24 hours
on the different substrates, both CDMs promoted similar
levels of cell attachment, which was significantly higher than
two-dimensional fibronectin (Figure 5a and b, left). Fibro-
blasts on the CDMs adopted an elongated, spindle shape
(Cukierman et al., 2001) as opposed to more round and
spread morphologies on the fibronectin control. The cell area
was largest on the fibronectin control, 2,704  112.5 mm2,
followed by sh1 CDM, 2,327  115.7 mm2, and NTC CDM,
1,901  81.63 mm2 (Figure 5b, middle). Interestingly, cells on
the knockdown CDMs appeared to have more projections
(Figure 5a). Finally, cell aspect ratio was significantly higher
on both CMDs than the fibronectin control (Figure 5b, right).
Type VI collagen has been associated with myofibroblast
differentiation (Naugle et al., 2006) and is expressed by adipo-
cytes (Pasarica et al., 2009). After 7 days of culture, almost all
fibroblasts were a-smooth muscle actin positive on the CDMs
and less so on the fibronectin control (Figure 5c and d, left). The
percentage of Ki67-positive cells was also higher on the CDMs
than the fibronectin control (Figure 5c and d, right). Oil red O
staining of the cultured cells revealed complete absence of
adipogenic differentiation for all three conditions (Figure 5e).
We then co-stained for phalloidin and fibronectin to visu-
alize the cells in relation to the CDMs. Cells on the type VI
collagen-depleted CDMs were oriented parallel with the
fibronectin fibers, in contrast with a more random orientation
for cells on the control CDMs (Figure 6a).We also explored the
role of type VI collagen in fibroblast migration by time-lapse
microscopy on the three different substrates. The cells dis-
played distinct migratory behaviors: they traveled the most
distance on the sh1 CDMs compared with the NTC and fibro-
nectin control, as illustrated by the representative cell track
plots (Figure 6b) and the migration movies (see Supplementary
Movie M1 online). Cells on the sh1 CDMs migrated with the
greatest speed, followedby cells on the control CDMs and then
two-dimensional fibronectin (Figure 6c, left). Cells on sh1
CDMs also exhibited slightly higher persistence compared
with NTC CDMs and fibronectin control (Figure 6c, right).
Taken together, these results indicate that type VI collagen in-
fluences fibroblast spreading, alignment, and motility but has
no effect on proliferation or differentiation.
The effects of type VI collagen depletion on cell migration
could also be observed between NTC CDMs from day 7 and
sh1 CDMs from day 10, at which point the thickness of both
matrices is approximately 8 mm, and cells migrated similarly
on two-dimensional surfaces coated with purified type VIJournal of Investigative Dermatology (2016), Volume 136collagen and fibronectin comparedwith fibronectin alone (see
Supplementary Figure S6 online). Consistent with previous
reports in which topographical cues from the ECM direct cell
migration (Kutys et al., 2013), we also find that dermal fibro-
blasts migrate along fibronectin-coated aligned polystyrene
fibers generated by electrospinning (see SupplementaryMovie
S2 online). These results therefore suggest that type VI
collagen-dependent changes in matrix structure, rather than
composition, regulate fibroblast motility.
DISCUSSION
The overall aim of this study was to investigate the role of type
VI collagen in the assembly of ECM by human dermal fibro-
blasts and evaluate the subsequent impact on cell behavior. By
characterizing CDMs generated by COL6A1 knockdown and
control fibroblasts, we demonstrated that type VI collagen
mediates ECM architecture and composition and affects
fibroblast morphology and migration. In conjunction with the
presence of type VI collagen throughout the dermis of intact
skin and within the newly formed granulation tissue of acute
wounds, these results suggest that it may play an important role
in wound repair. Thus, our findings provide insight into the
function of type VI collagen within the skin.
In agreementwith our studies, Sabatelli et al. (2001) observed
abnormal fibronectin deposition in the ECMfromfibroblasts of a
Bethlemmyopathypatient andalso fromCol6a1nullmice.Type
VI collagen has also been shown to modulate type I collagen
fibrillogenesis (Minamitani et al., 2004), and type I collagen fi-
brils appear irregular in UCMD patients’ skin (Kirschner et al.,
2005). Consistent with our results in the mouse, type VI
collagen is depositedduring theearly stagesofwoundhealing in
human skin, and its synthesis increases in parallel with type I
collagen, reaching a peak approximately 8 days after wounding
(Betz et al., 1993; Oono et al., 1993). Although Lettmann and
colleagues (2014) recently described no effects of type VI
collagen deficiency on overall wound closure time, both the
tensile strengthandcollagenfibril architectureweredisrupted in
the skin of Col6a1 null mice. Interestingly, we find that type VI
collagen is highly expressed at the expanding margins of keloid
scars, not only for African American earlobe samples (Peltonen
et al., 1991) but also foradditional ethnic groups andanatomical
sites including abdomen and occipital scalp. Given its role in
matrix assembly, type VI collagen may therefore contribute to
excess matrix deposition and the pathogenesis of keloid scar
formation.
The most striking effect of loss of type VI collagen in this
study was on fibroblast motility. Cells migrated with increased
speed and persistence on the highly aligned CDMs lacking
type VI collagen. Topography of the fibrillar network likely
directs migration; a more aligned matrix provides guidance
cues for rapid and directionally persistent cell movement
(Kutys et al., 2013). Furthermore, the increased spreading of
fibroblasts on the knockdown CDMs could potentially be
attributed to the increased interfibrillar spaces. Significantly,
these results demonstrate how type VI collagen-dependent
changes in the ECM directly impact dermal cell behavior.
Although it is clear that type VI collagen plays a key role in
regulating dermal tissue architecture and fibroblast function,
several important questions remain. For example, it is unclear
which specific subdomains within the protein interact with
Figure 5. Dermal fibroblast morphology is altered on collagen type VIedepleted cell-derived matrices (CDMs). (a) Fluorescence images of F-actin (green)
in primary dermal fibroblasts cultured for 24 hours on CDMs derived from nontargeting control (NTC) or sh1 expressing cells or on fibronectin (Fn)-coated
coverslips. (b) Quantification of fibroblast number, spread area, and aspect ratio on CDMs or fibronectin-coated surfaces. (c) Immunofluorescence images of
a-smooth muscle actin (aSMA, red) and Ki67 (green) expression in primary dermal fibroblasts cultured on CDMs derived from NTC or sh1 expressing cells or
fibronectin-coated coverslips for 7 days (no ascorbic acid in medium). (d) Quantification of aSMA and Ki67 positive cells on CDMs and fibronectin-coated
coverslips after 7 days. (e) Representative images of primary fibroblasts stained with oil red O and counterstained with hematoxylin after 7 days of culture on
CDMs or fibronectin surfaces. All data represent mean  s.e.m. (3 experiments). *P < 0.05, **P < 0.01, and ***P < 0.001 versus NTC; #P < 0.05, ##P < 0.01,
and ###P < 0.001 versus sh1. Scale bars: 25 mm.
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Figure 6. Type VI collagen-depleted
cell-derived matrices (CDMs)
enhance fibroblast motility.
(a) Immunofluorescence images
of primary fibroblast morphology
(F-actin, green) in relation to
fibronectin (Fn) fibers (red) of CDMs
generated by nontargeting control
(NTC) or sh1 expressing cells. (b)
Tracks of individual cells migrating on
CDMs or fibronectin-coated tissue
culture wells. Cells were imaged using
time-lapse phase-contrast microscopy
and analyzed with ImageJ. (c)
Quantification of single-cell velocity
and persistence (directionality) on
CDMs or fibronectin-coated tissue
culture wells. Data represent mean 
s.e.m. (4 experiments). *P < 0.05
and ***P < 0.001 versus NTC;
###P < 0.001 versus sh1. Scale bars:
25 mm.
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82other ECM components to control fibrillogenesis. We specu-
late that as a microfibrillar collagen that physically interacts
with fibrillar ECM components (for example, fibronectin and
collagen I), type VI collagen alters fibrillogenesis by displacing
other ECMcomponents, leading to fibril branching and amore
randomly oriented matrix. In addition to understanding the
molecular mechanisms by which type VI collagen controls
matrix assembly, it will also be interesting in future studies to
explore its role in aging and other skin pathologies, such as
chronic wounds. Finally, type VI collagen could be a potential
therapeutic target for tissue repair. Delivery of exogenous type
VI collagen may be advantageous for stimulating matrix
deposition, whereas inhibiting its expression may be desirable
for reducing fibrosis and scar formation. Thus, tuning the levels
of type VI collagen within the tissue could represent an
approach to modulating tissue regeneration.
MATERIALS AND METHODS
Human Tissue Samples
Skin samples were obtained from keloid patients and healthy vol-
unteers from the plastic surgery department at Barts Health NHS
Trust. Foreskin samples were obtained from neonatal circumcision
procedures. All subjects gave written, informed consent, and the
study was conducted under local ethical committee approval (East
London Research Ethics Committee, study no. 2011-000626-29) and
according to the Declaration of Helsinki. Details of patient skin are
listed in Supplementary Table S1.
Cell Culture
Primary dermal fibroblasts and HCA2 cell lines were cultured in
DMEM containing GlutaMAX (Gibco, Invitrogen, Paisley, UK), 10%
fetal bovine serum (labtech.com, Uckfield, UK), and 1% penicillinJournal of Investigative Dermatology (2016), Volume 136and streptomycin (Gibco, Invitrogen) at 37 C in a humidified at-
mosphere of 5% CO2:95% air. The culture medium was changed
every 2e3 days, and the cells were passaged at 70e80% confluency.
CDMs were generated as previously described with minor mod-
ifications (Beacham et al., 2007). Briefly, sterile 13-mm glass cov-
erslips were incubated with 0.2% sterile gelatin for 60 minutes at
37 C (gelatin type B; Sigma, St. Louis, MO). They were washed
three times with phosphate-buffered saline (PBS), cross-linked with
1% sterile glutaraldehyde for 30 minutes at room temperature, and
again washed three times with PBS. Cross-linking was quenched
with 1 M sterile glycine in PBS for 20 minutes at room temperature,
followed by washing three times with PBS and incubation in growth
medium (DMEM, 10% fetal bovine serum, 1% penicillin and
streptomycin) for 30 minutes at 37 C, and finally washing 3 times
with PBS. The coverslips were either used immediately or stored at
4 C for a maximum of 4 weeks. Dermal fibroblasts were plated at
a density of 60,000 cells per well and cultured overnight in 37 C,
5% CO2 to achieve full confluency. Medium supplemented with
50 mg/ml ascorbic acid was added and subsequently changed every
2 days. Cells were cultured for 10 days.
To denude cells, the medium was aspirated and cells washed
once with PBS. Prewarmed extraction buffer was then added
(10 mM NH4OH, 0.25% Triton X-100 in PBS) and left for 4 minutes
to allow cell lysis. Half of the buffer was carefully removed and PBS
added (Gibco, Invitrogen). The same step was repeated until no intact
cells were visible. The DNA residue was digested with 10 mg/ml
DNase I (Roche, Basel, Switzerland) in PBS for 30 minutes at 37 C,
5%CO2, followed by 2washeswith PBS.Matriceswere stored at 4
C
in PBS with penicillin and streptomycin for up to 4 weeks.
CONFLICT OF INTEREST
The authors state no conflict of interest.
G Theocharidis et al.
Type VI Collagen in Dermal Matrix AssemblyACKNOWLEDGMENTS
This work was funded by a PhD studentship from the Queen Mary EPSRC
Doctoral Training Account and the BBSRC project grant BB/J000914/1. We
thank Dr Matthew Caley for his assistance with paraffin sectioning and
providing the HCA2 cells, Dr Estelle Collin for her assistance with scanning
electron microscopy imaging, Dr Gary Warnes for flow sorting services, and
Profs Michael Philpott and Simon Myers for providing keloid tissue samples.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.
jidonline.org, and at http://dx.doi.org/10.1038/JID.2015.352.
REFERENCES
Beacham DA, Amatangelo MD, Cukierman E. Preparation of extracellular
matrices produced by cultured and primary fibroblasts. Curr Protoc Cell
Biol 2007;33:1e21.
Betz P, Nerlich A,Wilske J, et al. Immunohistochemical localization of collagen
types I and VI in human skin wounds. Int J Legal Med 1993;106:31e4.
Bidanset DJ, Guidry C, Rosenberg LC, et al. Binding of the proteoglycan
decorin to collagen type VI. J Biol Chem 1992;267:5250e6.
Bonaldo P, Russo V, Bucciotti F, et al. Structural and functional features of the
alpha 3 chain indicate a bridging role for chicken collagen VI in connective
tissues. Biochemistry 1990;29:1245e54.
Bran GM, Goessler UR, Hormann K, et al. Keloids: current concepts of
pathogenesis (review). Int J Mol Med 2009;24:283e93.
Brin˜as L, Richard P, Quijano-Roy S, et al. Early onset collagen VI myopathies:
genetic and clinical correlations. Ann Neurol 2010;68:511e20.
Brisson BK, Mauldin EA, Lei W, et al. Type III collagen directs stromal or-
ganization and limits metastasis in a murine model of breast cancer. Am J
Pathol 2015;185:1471e86.
Bushby KMD, Collins J, Hicks D. Collagen type VI myopathies. Adv Exp Med
Biol 2014;802:185e99.
Caskey RC, Zgheib C, Morris M, et al. Dysregulation of collagen production
in diabetes following recurrent skin injury: contribution to the development
of a chronic wound. Wound Repair Regen 2014;22:515e20.
Chen P, Cescon M, Bonaldo P. Lack of collagen VI promotes wound-induced
hair growth. J Invest Dermatol 2015;135:2358e68.
Chu ML, Conway D, Pan TC, et al. Amino acid sequence of the triple-helical
domain of human collagen type VI. J Biol Chem 1988;263:18601e6.
Collins J, Foley AR, Straub V, et al. Spontaneous keloid formation in patients
with Bethlem myopathy. Neurology 2012;79:2158.
Cukierman E, Pankov R, Stevens DR, et al. Taking cell-matrix adhesions to the
third dimension. Science 2001;294:1708e12.
Fitch JM, Birk DE, Linsenmayer C, et al. Stromal assemblies containing
collagen types IV and VI and fibronectin in the developing embryonic avian
cornea. Dev Biol 1991;144:379e91.
Fitzgerald J, Holden P, Hansen U. The expanded collagen VI family: new
chains and new questions. Connect Tissue Res 2013;54:345e50.
Fitzgerald J, Rich C, Zhou FH, et al. Three novel collagen VI chains, a4(VI),
a5(VI), and a6(VI). J Biol Chem 2008;283:20170e80.
Freise C, Erben U, Muche M, et al. The alpha 2 chain of collagen type VI
sequesters latent proforms of matrix-metalloproteinases and modulates
their activation and activity. Matrix Biol 2009;28:480e9.
Gara SK, Grumati P, Squarzoni S. Differential and restricted expression of
novel collagen VI chains in mouse. Matrix Biol 2011;30:248e57.
Gara SK, Grumati P, Urciuolo A, et al. Three novel collagen VI chains with high
homology to the alpha3 chain. J Biol Chem 2008;283:10658e70.
Herrick SE, Sloan P, McGurk M, et al. Sequential changes in histologic pattern
and extracellular matrix deposition during the healing of chronic venous
ulcers. Am J Pathol 1992;141:1085e95.
Hicks D, Farsani GT, Laval S, et al. Mutations in the collagen XII gene define a
new form of extracellular matrix-related myopathy. Hum Mol Genet
2014;23:2353e63.
Ishikawa O, Kondo A, Okada K, et al. Morphological and biochemical
analyses on fibroblasts and self-produced collagens in a novel three-
dimensional culture. Br J Dermatol 1997;136:6e11.
Jimenez-Mallebrera C, Maioli MA, Kim J, et al. A comparative analysis of
collagen VI production in muscle, skin and fibroblasts from 14 Ullrichcongenital muscular dystrophy patients with dominant and recessive
COL6A mutations. Neuromuscul Disord 2006;16:571e82.
Keene DR, Engvall E, Glanville RW. Ultrastructure of type VI collagen in
human skin and cartilage suggests an anchoring function for this filamen-
tous network. J Cell Biol 1988;107:1995e2006.
Kirschner J, Hausser I, Zou Y, et al. Ullrich congenital muscular dystrophy:
Connective tissue abnormalities in the skin support overlap with Ehlers-
Danlos syndromes. Am J Med Genet 2005;132A:296e301.
Kuo HJ, Maslen CL, Keene DR, et al. Type VI collagen anchors endothelial
basement membranes by interacting with type IV collagen. J Biol Chem
1997;272:26522e9.
Kutys ML, Doyle AD, Yamada KM. Regulation of cell adhesion and migration
by cell-derived matrices. Exp Cell Res 2013;319:2434e9.
Lettmann S, Bloch W, Maaß T, et al. Col6a1 null mice as a model to study skin
phenotypes in patients with collagen VI related myopathies: expression of
classical and novel collagen VI variants during wound healing. PLoS ONE
2014;9:e105686.
Minamitani T, Ikuta T, Saito Y, et al. Modulation of collagen fibrillogenesis
by tenascin-X and type VI collagen. Exp Cell Res 2004;298:305e15.
Naugle JE, Olson ER, Zhang X, et al. Type VI collagen induces cardiac
myofibroblast differentiation: implications for postinfarction remodeling.
Am J Physiol Heart Circ Physiol 2006;290:H323e30.
Oono T, Specks U, Eckes B, et al. Expression of type VI collagen mRNA during
wound healing. J Invest Dermatol 1993;100:329e34.
Pan T-C, Zhang R-Z, Markova D, et al. COL6A3 protein deficiency in mice
leads to muscle and tendon defects similar to human collagen VI
congenital muscular dystrophy. J Biol Chem 2013;288:14320e31.
Pasarica M, Gowronska-Kozak B, Burk D, et al. Adipose tissue collagen VI in
obesity. J Clin Endocrinol Metab 2009;94:5155e62.
Peltonen J, Hsiao LL, Jaakkola S, et al. Activation of collagen gene expression
in keloids: co-localization of type I and VI collagen and transforming
growth factor-beta 1 mRNA. J Invest Dermatol 1991;97:240e8.
Ruehl M, Somasundaram R, Schoenfelder I, et al. The epithelial mitogen
keratinocyte growth factor binds to collagens via the consensus sequence
glycine-proline-hydroxyproline. J Biol Chem 2002;277:26872e8.
Sabatelli P, Bonaldo P, Lattanzi G, et al. Collagen VI deficiency affects the
organization of fibronectin in the extracellular matrix of cultured fibro-
blasts. Matrix Biol 2001;20:475e86.
Sabatelli P, Gara SK, Grumati P, et al. Expression of the collagen VI a5 and a6
chains in normal human skin and in skin of patients with collagen VI-
related myopathies. J Invest Dermatol 2011;131:99e107.
Saroja AO, Naik KR, Nalini A, et al. Bethlem myopathy: an autosomal
dominant myopathy with flexion contractures, keloids, and follicular
hyperkeratosis. Ann Indian Acad Neurol 2013;16:712e5.
Singer AJ, Clark RA. Cutaneouswound healing.N Engl JMed 1999;341:738e46.
Somasundaram R, Ruehl M, Schaefer B, et al. Interstitial collagens I, III, and
VI sequester and modulate the multifunctional cytokine oncostatin M.
J Biol Chem 2002;277:3242e6.
Somasundaram R, Ruehl M, Tiling N, et al. Collagens serve as an extracellular
store of bioactive interleukin 2. J Biol Chem 2000;275:38170e5.
Somasundaram R, Schuppan D. Type I, II, III, IV, V, and VI collagens serve as
extracellular ligands for the isoforms of platelet-derived growth factor (AA,
BB, and AB). J Biol Chem 1996;271:26884e91.
Specks U, Mayer U, Nischt R, et al. Structure of recombinant N-terminal
globule of type VI collagen alpha 3 chain and its binding to heparin and
hyaluronan. EMBO J 1992;11:4281e90.
Stephens P, Grenard P, Aeschlimann P, et al. Crosslinking and G-protein
functions of transglutaminase 2 contribute differentially to fibroblast wound
healing responses. J Cell Sci 2004;117:3389e403.
Tillet E, Wiedemann H, Golbik R, et al. Recombinant expression and struc-
tural and binding properties of a1(VI) and a2(VI) chains of human collagen
type VI. Eur J Biochem 1994;221:177e87.
Von der Mark H, Aumailley M, Wick G, et al. Immunochemistry, genuine size
and tissue localization of collagen VI. Eur J Biochem 1984;142:493e502.
WibergC,HedbomE,KhairullinaA, et al. Biglycananddecorinbindclose to then-
terminal regionof thecollagenVI triplehelix. JBiolChem2001;276:18947e52.
Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing
and its impact on abnormal scarring. Adv Wound Care 2013;4:119e36.www.jidonline.org 83
